Is GIP agonism or antagonism the metabolically useful direction?

The receptor pharmacology I can follow; the in vivo translation is where I lose the thread.

I would like the axes of comparison first and the recommendation second.

I have tried the first option and it works; the question is whether the second is better rather than merely different.

What is the actual trade-off, and does it matter at the scale I am working at?

Mechanically, start from the receptor and the rest follows: which receptors, in what ratio, with what signalling bias, reached at what concentration.

Orforglipron is not a peptide at all, which changes everything downstream: it is orally bioavailable without an absorption enhancer, it has no fasting or water requirement of the same kind, it does not require cold chain, and it cannot be assayed by any of the peptide methods discussed elsewhere on this site.

On the detail: oral bioavailability of a 4 kDa peptide is essentially zero without help. Oral semaglutide is co-formulated with sodium N-(8-[2-hydroxybenzoyl]amino)caprylate, which raises local gastric pH and transiently increases transcellular permeability in a small area of gastric mucosa. It works, and it delivers roughly one per cent of the dose, which is why the oral tablet strengths are an order of magnitude above the injectable and why fasting and water volume are not optional details.

Oral semaglutide’s absorption mechanism via SNAC is described in the pharmacokinetic literature, and the ~1 per cent bioavailability figure with high inter- and intra-individual variability is why administration conditions are specified so tightly[1].

I would separate what is established structurally from what is inferred clinically. The chemistry is settled; the attribution of clinical effect to specific receptor arms mostly is not.

The mechanism is settled enough to be useful and unsettled enough to be interesting, which is a reasonable place for a field to be.

edited 15 Mar 2026 by Dr_Ilse_Vandenberg — fixed an arithmetic slip in the third paragraph

On the detail: the mechanism question has a clean answer for the peripheral effects and a much less clean answer for the central ones, and it is worth being explicit about which of those you are asking about.

The GIP agonism-versus-antagonism question remains open, and the awkward fact is that both directions have produced weight loss in humans. The reconciling hypothesis is that chronic GIPR agonism produces receptor desensitisation and therefore functions as a pharmacological antagonist, but that is a hypothesis fitted to the data rather than an independent finding.

Comparing a 2.4 mg dose of one agonist to a 15 mg dose of another tells you nothing, because the molar potencies at their respective receptors differ, the receptor profiles differ, and the exposure per milligram differs. The only defensible comparison is between clinical outcomes in trials with comparable populations and durations, which is why SURMOUNT-5 exists and why indirect comparisons should be read sceptically.

The structural basis of semaglutide’s pharmacokinetics — Aib-8, the Arg34Lys substitution and the C18 diacid–AEEA linker at Lys26 — is described in the original medicinal chemistry publication, and it is worth reading once because it makes the design logic explicit[1].

The chemistry is the interesting part and it is also the well-documented part. Read the medicinal chemistry papers; they are short and they explain the design.

GLP-1R is a class B G-protein-coupled receptor signalling predominantly through Gs and cyclic AMP, and most of the interesting pharmacology in this class is about where that signalling happens rather than how hard it is driven.

Receptor desensitisation as a plateau mechanism is plausible and poorly evidenced. GLP-1R internalises on agonist binding and recycles, and biased agonists that internalise less have been argued to sustain signalling better. Whether any of that operates at the timescale of a four-month clinical plateau — against the much simpler explanation that energy expenditure fell with mass — is not established.

Retatrutide’s Phase 2 dose-ranging results reported dose-dependent weight reduction with a tri-agonist across a range of doses, and the magnitude at the top dose is what motivated the Phase 3 TRIUMPH programme[1].

Structure predicts pharmacokinetics reliably and clinical effect unreliably. Keep the two claims separate.

Dose equivalence across agents with different receptor profiles is not a defensible concept, and the attempt to construct it is the most common analytical error in this area.

Amylin co-agonism adds to a GLP-1 effect rather than duplicating it because the two act through different circuits: amylin signals through the area postrema via calcitonin receptor complexes, GLP-1 through both the area postrema and the arcuate nucleus. Two non-redundant satiety signals summate, which is the design rationale for a co-formulation rather than a higher dose of either.

The role of the area postrema and the hypothalamic arcuate nucleus in GLP-1-mediated appetite suppression is supported by both the neuroanatomy of receptor expression and by the effect of lesioning studies in animal models.

If you want to reason about a new agent, start from its receptor profile and its half-life. Almost everything else follows.